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Abstract
Background: The creation and exchange of knowledge between cultures has benefited world development for
many years. The European Union now puts research and innovation at the front of its economic strategy. In the
health field, biomedical research, which benefits the pharmaceutical and biotechnology industries, has been well
supported, but much less emphasis has been given to public health and health systems research. A similar picture
is emerging in European support for globalisation and health
Case studies: Two case-studies illustrate the links of European support in global health research with industry and
biomedicine. The European Commission’s directorates for (respectively) Health, Development and Research held an
international conference in Brussels in June 2010. Two of six thematic sessions related to research: one was solely
concerned with drug development and the protection of intellectual property. Two European Union-supported
health research projects in India show a similar trend. The Euro-India Research Centre was created to support
India’s participation in EU research programmes, but almost all of the health research projects have been in
biotechnology. New INDIGO, a network led by the French national research agency CNRS, has chosen
‘Biotechnology and Health’ and funded projects only within three laboratory sciences.
Discussion: Research for commerce supports only one side of economic development. Innovative technologies
can be social as well as physical, and be as likely to benefit society and the economy. Global health research
agendas to meet the Millenium goals need to prioritise prevention and service delivery. Public interest can be
voiced through civil society organisations, able to support social research and public-health interventions. Money
for health research comes from public budgets, or indirectly through healthcare costs. European ‘Science in
Society’ programme contrasts research for ‘economy’, using technical solutions, commercialisation and a passive
consumer voice for civil society, compared with research valuing ‘collectivity’, organisational and social innovations,
open use, and public accountability.
Conclusions: European policy currently prioritises health research in support of industry. European institutions and
national governments must also support research and innovation in health and social systems, and promote civil
society participation, to meet the challenges of globalisation.
Introduction
T h i sp a p e ri so n ei nas e r i e so fp a p e r si nGlobalisation
and Health following the seminar ‘Health systems,
health economies and globalisation: social science per-
spectives’ held at the London School of Economics in
July 2010 with participants jointly from UK and India. It
asks, from a European and global perspective, what
knowledge will best promote health. The Background
presents a historical example of the globalisation of
knowledge. The European Perspectives section describes
development of the European ‘knowledge-based econ-
omy’, policies and structures for research, and the posi-
tion of health research. Two Case-study examples
follow, of European engagement with globalisation and
health in India. The Discussion considers the implica-
tions for health of for-profit research, the role of civil
society organisations, and the contribution that social
sciences can give to globalisation and public health.
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Globalisation of knowledge
The expansion of trade, communication and travel that
is implied in the term globalisation has been a gradual
process over past centuries, but with increasing speed
and impact into the present century. Ideas and knowl-
edge are significant features within this process, control-
ling both development within countries and also
available for exchange and trade themselves. A remark-
able example from a European perspective is described
by Menzies [1] in a controversial book entitled ‘1434’.
He suggests that arrival in Venice of ships from China
in that year, originating from a grand fleet sent west-
wards to demonstrate China’s power and advanced cul-
ture to the world, contributed substantially to
globalisation through the diffusion of knowledge. Men-
zies contends that the technologies developed and well
known to the Chinese suddenly emerged in renaissance
Italy. He shows that the drawings of technologies across
a wide range of fields, from canal locks, to winches, to
helicopters, by Leonardo da Vinci had been printed in
practical books circulating in China a century pre-
viously. Shortly after, with changing politics at home,
the east closed its doors to the west But the new tech-
nologies fed into the reformation and Europe’s industrial
development. Now, in the electronic era, leadership in
technology that moved from Europe to America in the
twentieth century is againr a n g i n ga c r o s st h ew h o l e
world.
Science, technology and innovation are important dri-
vers of economic change, although innovation is rarely
instant and older technologies continue both in the
world and within countries for long periods in the face
of alternatives that may be cheaper, speedier or less pol-
luting [2]. New methods of production, new products
and new social organisations can create competitive
advantage [3] that leads to economic advancement - the
aim now of almost all political systems. Science is neu-
tral but its effects can be political [4], enabling wars as
well as wealth [5], and indeed the pressures of war have
also led to new technologies. The direction of science
towards humanitarian ends is particularly demonstrated
in health science, but the underlying purpose of knowl-
edge for (here social) development is the same. Since
science and technology produces wealth, politicians
want it.
The challenge for creative scientists is to direct knowl-
edge across the full range of cultural development.
‘Technologies’ can be social as well as mechanical. One
of the recognised innovations in the UK during the Sec-
ond World War was ‘operational research’,i nw h i c h
scientific systems of thinking (especially mathematics)
were applied to real-world problem-solving [6]. Simi-
larly, the 1942 Beveridge Report, setting out a new
system for social justice in Britain, also resulted from
collective pressures of a war which impacted not just on
forces overseas but also on the civil population at home.
Now in the health field, social innovations in the organi-
sation of services and care, and in the prevention of dis-
ease through changing behaviours and social
determinants, are creating new ways of understanding
and controlling both the physical and the social worlds.
European Perspectives
Science in Europe
The priority of invention and achievements in science
by China before the European renaissance were estab-
lished by Joseph Needham [7]. India’s scientific achieve-
ments are less well researched, although steel was an
early invention, as shown in the rust-free iron pillar in
Delhi dated 402CE [8]. Europe has been at the forefront
of science and technology in the recent past, and wishes
to be so in the future. In contrast to the Imperial
model, however, Europe - developing from city-republics
[9] - inclines to a decentralised competitive model.
Towns, regions and countries compete with each other;
individuals compete, and use legal patents to own exclu-
sive rights for intellectual property; and now universities,
the contemporary knowledge institutions, compete to
attact students for income and faculty members to pro-
mote research ratings and enhance prestige.
The European Union now includes most of the coun-
tries of geographical Europe. It remains relatively weak
at national level, as the member states retain the main
levers of economic control, and the European Union’s
own budget is only 1% of the total European GNP. Yet
the European Union has two great strengths: it is a fra-
mework for international collaboration that is increas-
ingly accepted and welcomed by its citizens; and it
holds, in its legal directives, the means for long-term
regulation and convergence of economic and social
practices. Implementing the laws required of the Eur-
opean aquis communautaire has been a major factor in
transforming the former communist states of Eastern
Europe.
The European Union has three main structures: the
Council of Ministers - the political heads of member
states, approving laws; the European Parliament -
directly elected parliamentarians debating policies; and
the European Commission - the administration, holding
both budget and bureaucracy and therefore executive
power. The Commission has ‘directorates’, each headed
by a Commissioner, similar to ministries in member
states. Science was a field for collaboration relatively
early in the European Community (the antecedent of
the European Union). In the 1970 s, the directorate for
research developed programmes initiating cooperation
between European academics. It offered grants for travel
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tutes (eg CERN) to bring European scientist together on
one campus. From the perspective of European Com-
munity legal competence, biomedical research was
accepted from the 1970 s as within the field of science;
and biomedicine has taken a rising proportion of the
enlarging budget within the Research Framework Pro-
grammes [10]. On the other hand ‘health’ was regarded
as outside European competence until the 1992 Treaty
of Maastricht. This thinking, that biomedicine ‘science’
is within DG Research, while public health and health
systems are separate within DG Health - and without a
strong research perspective - has persisted to the
present.
The European Union’s Lisbon Strategy in 2000 pro-
posed that Europe should become the ‘leading knowl-
edge-based economy’ in the world by 2010 [11]. There
should be more funding for research, the knowledge
gained should be used to develop new products for
competitive international markets, and business should
contribute a higher proportion of funds. Yet this hope
has not been fulfilled. In 2010, the average for R&D
spending in the European Union remained below 2% of
total GDP, compared with 2.6% in the US and 3.4% in
Japan. This difference is mainly due to less R&D by pri-
vate companies in Europe [12].
The European Union funds only a small proportion of
all science in Europe, which is mostly financed from
national resources; and in some areas, European colla-
boration is not high on the agenda. For example, mem-
ber states have been cautious in signing up to the
European Commission’s ‘Joint Programming Initiative’
which hopes to create common collaborative research
programmes [13]. Yet from the view-point of European
Commission administrators seeking to expand the
science and innovation base in Europe, the research pro-
gramme is an important instrument for dissemination
and economic development, providing technology trans-
fer between collaborative teams and funds for setting up
new activities. ‘Innovation’ is the leading theme of the
EU economic strategy to 2020 [14]. The European
Union’s Structural Funds, one third of total EU
resources, have earmarked around 10% for support for
research, both in people (funding for training and early
careers) and facilites (such as ‘science parks’).
European health research
’Health’ is the term increasingly used for the field for-
merly known as ‘medicine’. The World Health Organisa-
tion, in its 1948 founding articles, described health as ‘a
complete state of physical, mental and social well-being,
and not merely the absence of disease or infirmity’.T h i s
raises the bar high, since most ‘health’ services are still
primarily oriented to patients consulting with disease,
and most healthcare resources are spent on citizens in
their last year of life (and thus trajectory to death). Yet
‘health’ recognises the need to understand and respond
to people on biological, social and psychological planes.
If you define medicine to encompass these already - as
some physicians and philosphers have done over the cen-
turies - then there are grounds for retaining the word
medicine. But issues of power have intruded. The author-
ity of ‘medical’ doctors in defining and treating disease is
challenged by other workforce disciplines ‘allied’ to medi-
cine performing tasks for patients (nursing, caring), or
who reject ‘medicalisation’ [15] of human experience.
Similarly, there is a criticism of equating health with
‘wellbeing’ and ‘happiness’, which are unstable subjective
measures, as though these are equivalent to ‘disease’ that
is addressed by medical doctors.
The European Commission’s fourth and fifth Research
Framework Programmes included BIOMED 1 and 2
(1994-2002), which emphasised life sciences and basic
biology, and gave some support for epidemiology. For
the sixth Research Framework Programme, covering the
years 2002-2006, there was a substantial shift [10]. With
the development of new technologies of recombinant
genetics, a high proportion of the biology and medical
budget was directed towards genetics, while ‘health’
themes were relegated to a separate ‘policy research’
strand. For the seventh Research Framework Pro-
gramme (2007-2013), the main focus has been on dis-
eases (cancer, heart disease, respiratory disease etc) that
match medical specialties and pharmaceutical
approaches. The new paradigm is ‘translational
research’, seeking to use existing, and develop new,
knowledge to provide more effective treatments - and to
‘translate’ research into marketable and profit-making
products. Nevertheless, as well as molecular and clinical
research, the seventh Research Framework Programme
has also a ‘pillar’ for public health, which includes health
determinants and health systems research - although it
receives only around 5% of the total research budget in
the Health theme.
While there remain substantial bureaucratic obstacles
f o rt h er e s e a c h e rt oo v e r c o m ei na p p l y i n gf o rf u n d s ,s e v -
eral structural changes have made accessing the Eur-
opean research programmes more attractive: the funds
can now be used for all researchers including the work of
those with tenured positions; there are mechanisms to
draw on national co-funding; individual single-country
science projects are now supported through the new Eur-
opean Research Council; and countries across the world
are able to participate if they contribute to the project.
Global health research
While the term ‘health research’ is mostly used today to
include laboratory, clinical and population-level
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Health Research, set up with support of the World
Health Organisation following the landmark report of
the Commission on Health Research for Development
[16], has revised the term to ‘research for health’ in an
attempt to emphasise public-health concerns for the
population-level determinants of disease, as well as
treatment [17]. Equally, there is growing recognition of
‘health research systems’, the organisational, social and
economic frameworks that support health research.
Funding of research in low and middle income countries
led by the Gates Foundation for treatment of HIV, TB
and malaria has come sharply up against the importance
of healthcare delivery, access and uptake research to
maximise success of laboratory-to-bedside programmes.
And the contribution of prevention in reducing the glo-
bal burden of diseases is recognised in the emerging
agenda for chronic diseases research [18].
Historically, health research in low and middle income
countries has been a mix of national and international
programmes. The USA (for example, the Fogarty Inter-
national Centre at the US National Institutes of Health)
and European countries individually have been donors,
sometimes tied to specific research institutes [19]. Since
the report of the Commission for Health Research for
Development [16], WHO has encouraged its member
states to develop national health research strategies and
programmes. The response has been patchy, as indicated
by the limited number of countries with full descriptions
on the website of the Council on Health Research for
Development [20], but thriving indigenous research is
expected to increase relevant research, to support
researchers fostering the next generation, and to reduce
the brain drain to western countries.
The European Commission had collaboration with
‘third countries and international organisations’ in its
research programmes since 1994. This capability was
included in the thematic programmes (health, food, IT
etc) in the seventh Framework Research Programme
(FP7). At the same time, the rules of FP7 were widened
to allow applications, not just as partners but also as
leaders, from almost all countries in the world, and for
a focusing of calls on regions and across themes. For
2010, the FP7 programme brought together an ‘Africa’
research call from research topics (and funding) within
the themes of agriculture, food and transport as well as
health. And the instrument of ‘ERA-nets’,n e t w o r k so f
national research organisations, can help researchers
join together in planning research and feed ideas into
the European programmes.
It may seem that there has been a slow European
awareness of the needs for global health research. The
torch for collaboration was kept in earlier years by a few
countries in a semi-postcolonial way, with research
programmes determined by the donor country, and the
lack of technology infrastructures as well as financial
attractions have led laboratory scientists to migrate to
western countries. Nevertheless, the conjunction of the
Report of the Commission on Health Research for
Development, the financial resources of the Gates Foun-
dation and the international concern on millenium
development goals changed the situation markedly. The
new agenda of globalisation brings new players to the
table and alters the dynamics of priorities, incentives
and practice [17].
There have also been important impacts and changes
in direction. Beyond trials and marketing of pharmaceu-
ticals, there is now recognition of research on delivery
systems, health cultures and behaviours including
uptake, and wider determinants. The trials of low tech-
nologies such as bed nets, and economic incentives such
as micro-payments, are changing the paradigm of health
research, bringing in local communities, requiring differ-
ent governance and seeking different end points [21].
The European Union’s economic and research policies
are oriented towards innovation in support of economic
development. EU support for health research emphasises
biomedicine and technology, but there is less support
for public health and health systems research. Two case-
study examples in relation to globalisation are given
below, and the Discussion considers three themes aris-
ing - contrasting research for private and public gain,
the role of civil society organisations, and perspectives
of social sciences.
Case-studies
Globalisation and Health at the European Commission
The European Commission Global Health Conference,
held in Brussels in June 2010 [22] brought together
three of the Commission’s directorates with overlapping
interests - the Directorate General (DG) for Health, DG
Development and DG Research. These are not large
spending directorates: two thirds of European Commis-
sion’s annual funding of €141 bn are spent on the Com-
mon Agricultural Policy and the Regional Funds (which
are directed towards the poorer countries and regions of
Europe) [23]. DG Research has €7.5 bn (5% of the Eur-
opean Union’s budget), DG Development €3 bn (2%) for
direct overseas aid, and the DG Health and Consumers’
budget, at €50 million, is just 0.1% of the whole total
budget. The seventh Framework Research Programme
allows applications from countries around the world
when the researchers are collaborating with Europe.
The Conference had two days, of which the first was
identified as technical and the second political. This
reflected the structure of inter-governmental confer-
ences such as the recent UN Climate Change confer-
ence, with initial work leading to final political
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of the European Commission’sB r u s s e l sC h a r l e m a g n e
building hall, were invited through European representa-
tive organisations rather than member states alone. The
opening sessions on health and development were given
contemporary political emphasis with the words
‘inequalities’ and ‘rights’, although these were concerned
more with moral debates than with practical and politi-
cal questions of how to achieve balanced global eco-
nomic development and thereby greater health for all.
There was discussion on broad health issues, including
workforce, communicable diseases and non-communic-
able diseases. Country-led international health strategies
were presented, and the policies and programmes of the
European Commission. Yet research was considered
particularly from the paradigm of commercialisation by
European pharmaceuticals manufacturers, and the pro-
tection of intellectual property. Of two workshops
devoted to health, all six speakers in the workshop ses-
sion ‘Innovation’ took this approach, explicitly promot-
ing research for industry [22].
Europe-India health research
Two examples of European collaboration with India on
research in relation to health are considered. The Euro-
India Research Centre (EIRC) has been established as
“an information service to facilitate collaboration
between Indian and European organisations (from
industry and academia) for conducting joint RT&D
through FP7” [24]. This coordinating support includes a
National Contact Point service for liaison on specific
research fields and calls as well as liaison for project
implementation. Since 2007, there have been more than
140 partners in successful FP7 proposals, including 20
for the health calls. However, within the health projects
in 2007, and despite the profound needs fof India, public
health research was given very little precedence: 17 were
for biomedicine, 2 were for health financing and one
was a generic support network. In the Science in Society
call, one of the four successful projects was for health -
about patent protection in the pharmaceutical industry.
New INDIGO, an FP7 project led by the French
national research agency CNRS, seeks to promote scien-
tific collaboration and access to the European Research
Area [25]. While providing a service across all scientific
areas, New INDIGO chose to make its first call for
funding of networking projects to start in 2010 in the
field of ‘Biotechnology and Health’. In this call, the three
fields specified for proposals were all laboratory sciences
- biomarkers and diagnostics, bioinformatics, and struc-
tural biology. Indeed, to emphasise the priority for
industry research, New INDIGO web page noted as
‘Important’ on its ‘News’ a Flagship Mission to India for
biotech SMEs (small and medium enterprises). The
event is advertised as ‘an opportunity to enter one of
the world’s fastest emerging biotech markets’,f r o mM a y
30th to June 4th 2010 in Bangalore, where ‘EU partici-
pants will benefit from podium presentations to a
selected audience of Indian public and private business
and research organisations; [and a] customised schedule
of one-on-one business meetings with pre-screened
Indian potential partners, agents, distributors, licensees,
and retailers’ [25].
Discussion
Globalisation is the new framework for understanding
economic and commercial development, for addressing
issues of environmental sustainability, for security and
social justice. Health and research are part of this
agenda, but what science is needed?
Research for private and public gain
The European Commission’s Globalisation and Health
conference [22] was framed around European Union’s
policies and practices - spreading European influence by
‘soft’ means of discussion, exchange and funding, rather
than ‘hard’ means of trade and war. The conference
included participants expected to be critics, in the forms
of NGOs and academics, as well as politicians. But the
research theme debate left unresolved the crucial
choices between international research for the private
sector and for the public sector, and thereby the balance
between research for medicine and research for health.
The Europe 2020 strategy [12] proposes a ‘knowledge-
based economy’ through research and innovation for
sustainable development. The policy of national research
budgets growing to 3% of GDP is also maintained, with
a continued emphasis on research to be funded by
industry. DG Research has put effort into linking so-
called small and medium enterprises (SMEs) with the
publicly-funded research programmes, hoping to create
synergy and expansion: an example is SMEs-Go-Health
[26], a coordinating organisation providing support for
“research-intensive, high technology SMEs” to join
research consortia. Yet most SMEs, by the EU definition
employing fewer 250 people, are usually without any
research capability. Sometimes they can access research
organisations providing services to small companies, but
the research is mainly ‘near product’. The strategy also
encourages the protection of intellectual property
through patents - away from a traditional European
humanistic view that knowledge is universal. And
experience is mounting (anecdotally) within DG
Research of SMEs involved in research consortia that do
well in the first year of the project but fail in the second
- a feature much less common in public sector research.
There is an increased pressure to invest in technologi-
cal research, and for companies to gain financial return
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systems are publicly regulated and paternalistic, and
‘trade’ is at cost to the public as payers of health insur-
ance and taxes. Equally, the emphasis on laboratory
research gives less value to social, behavioural and orga-
nisational research. The emphasis on developing effec-
tive medical interventions has led to a new paradigm of
‘translational’ research, which seeks to link the ‘labora-
tory’ to the ‘bedside’. And this paradigm is increasingly
driven by commercial interests. It is difficult to intro-
duce the idea that the determinants of health lie outside
the laboratory, in the wider aspects of society and econ-
omy, and that ‘translational’ research on effective inter-
ventions in this wider public-health field is as relevant
to the health sector as narrower clinical research [27].
The pharmaceutical industry uses developmental work
extensively, with a paradigm of steps from laboratory to
human clinical trials (phase 1 to phase 4 trials) now
enshrined by regulating agencies. By contrast, public-
health innovation actions have no strategic framework
equivalent to pharmaceutical research. They are usually
described as ‘projects’, often one-off, context-specific,
isolated from other equivalent work, without replication
or scale-up, and perhaps weakly evaluated (including
lack of economic evaluation). Prospective observational
epidemiological research is funded, but large public
health intervention studies are rare. As a result, regula-
tory agencies have limited evidence to promote effective
public-health interventions, and also not able to reject
those which are ineffective. Innovations in disease pre-
vention and health promotion develop independently in
European countries, with less joint learning and with
resulting waste of resources.
The argument here is two-fold. First, that within medi-
cal research there should be greater emphasis on public
health and health systems research - and a reduction in
investment on pharmaceuticals research - because the
health gain will be greater. There is a social benfit from
not-for-profit, or non-patentable, research. Second, social
and services innovation should be recongised to be as
beneficial as for-profit, patentable research. There are
physical technologies and there are social technologies:
disease treatment may use physical treatments while dis-
ease prevention can use social and behavioural interven-
tions. As well as recognising the need for innovation for
both business and services “in all sectors, including the
public sector”, the European Commission proposes “new
ways of meeting social needs which are not adequately
met by the market or the public sector” [14].
The health challenge of globalisation is how to suc-
ceed within the wider for-profit market system. Corpo-
rate capitalism seeks not just to be within a market, but
to control it [28]. If research and innovation are the
basis for commercial success, capitalism will seek to
control and direct them towards corporate rather than
public benefit. The European Union has policies for
innovation which are stated to address social as well as
economic issues. However,t h em e a n i n go fs o c i a lm a y
be ‘more and better jobs and increased social cohesion’,
that is employment protection, rather than broader
actions for the benefit of society as a whole.
The returns from research and innovation, and their
implementation in health and healthcare systems, should
be calculated and set against the costs of alternatives.
The pharmaceutical industry is closely linked to the
major global donor in the health field, the Gates Foun-
dation, promoting the paradigm of treatment for dis-
eases (HIV, TB, malaria) that are also preventable by
alternative social public strategies and investment.
Funds go into treatment of patients now while further
cases arise, a ‘downstream’ policy which perpertuates
the disease and thus the response. Thus, while pro-
grammes for drug treatment of HIV have been rolled
out with the strong support of industry, the Global HIV
Prevention Group [29] have estimated that scale-up of
existing prevention tools would lower the incidence of
HIV by nearly two-thirds by 2015. Since the total
research capacity is limited, economics should compare
investment in public-health research in competition
with, rather than in addition to, pharmaceutical
research. Health research can provide a balance in
approaches and to deliver sufficient evidence to influ-
ence policy and practice in more socially beneficial ways.
Civil society
One contribution to balance research to benefit industry
can come through civil society organisations (CSOs).
There is a growing literatureo np u b l i ci n v o l v e m e n ti n
health research in low-and middle-income countries
[30]. Areas of involvement have included developing the
research agenda, design, methods and impacts. Studies
report benefits - and difficulties - for researchers,
research participants and community organisations; but
there is little research published on the impact of public
involvement on research funding and commissioning.
Yet civil society organisations are interested also in the
systems of health research. In STEPS [31], funded by
the Science in Society theme of FP7, CSOs in the twelve
EU new member states have organised workshop meet-
ings with researchers and national health research com-
missioners. The sessions showed a strong interest from
the CSO participants: as well as applying knowledge
passed from others to be implemented as practice, they
also see themselves promoting research themes and
being part of the research development process.
In most European health research with civil society
involvement, the focus has been patients rather than the
public [32]. In a study of the UK health research system,
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groups tend to push for more research in their particular
fields, and the lack of a strong advocacy group for public
health may have contributed to the traditionally low
levels of funding in that area’. For example, in the field of
rare diseases, the pharmaceutical industry has been assid-
uous in promoting, and indeed often rewarding, patient
involvement: the ‘European Patients Forum’ is almost
fully funded by six pharmaceutical companies [34].
But engagement of civil society organisations is also
promoted by the Global Forum for Health Research. In
2010, working with the People’s Health Movement, a
call was made for research proposals from civil society
o r g a n i z a t i o n s[ 3 5 ] .C S O sw e r es e e na sp a r t i c i p a n t si n
the entire research process, from design through to dis-
semination, and could contribute to proposing interven-
tions and evaluation methods, as well as influencing
policy choices and uptake of research into practice.
There were 93 proposals received, from 53 countries
and across 5 languages. Four selected research proposals
are to be supported with mentoring, networking and a
cash award of up to USD 10,000. This initiative begins
to balance the involvement of for-profit industry in low
and middle income countries.
Social science perspectives
Public health, which brings social sciences into dialo-
gue with bio-medical sciences, has to argue its case
for action. Epidemiology is able to demonstrate risks
and associations quantitatively, and to monitor and
demonstrate impacts from interventions. In much
public health science where the randomised controlled
trial is difficult to apply, methods are often descriptive
and inferences of risks and benefits have to be consid-
ered through non-experimental criteria [36]. Yet even
where a well-conducted trial has shown compelling
benefit, for example, in prevention of neural tube
defects with folates, policy-makers may delay public
programmes [37].
Surveying the public health research systems in Eur-
opean member states, the lack of development of social
sciences for health research was evident [38]: the main
recipients of national research funds were the traditional
science academies, while the ministries of health funded
public-health institutes mainly undertaking laboratory
and sanitation sciences. In western European countries,
social sciences have developed within universities, pro-
ducing both quantitative and qualitative research, and
linking to health services research, health promotion
and health economics. These social science inputs com-
plement medical science and practice in public-health:
research needs to address both social and biological
determinants of disease, and the effectiveness, efficiency
and equity of the health system.
How does the emphasis, in the Lisbon Agenda, on
science for innovation by the commercial sector match
the needs of health research at European and global
levels [39]? Steiglitz [40] and Chen et al [41] developed
the case for both knowledge and health as ‘global public
goods’ in a colloquium by the United Nations Develop-
ment Project. The challenge to health has come in the
past decade through pressure from global pharmaceuti-
cal companies to maintain profits in the face of interna-
tional concern for access to drugs [42]. The World
Health Organisation’s so-called ‘Global strategy and plan
of action on public health, innovation and intellectual
property’ is only passingly about public health and very
much about intellectual property protection. But the
European discourse can be broader: for example, the
European Commission Research Directorate’s ‘Science
in Society’ programme [43] has proposed a balance
between an approach valuing ‘economy’,w i t ht e c h n o l o -
gical solutions of social problems and a passive (consu-
mer’s) role of civil society, compared with research
valuing ‘collectivity’, with more low-tech and social
innovations, unrestricted transfer and use of knowledge
(while supporting traceability of their origin and influ-
ence), and emphasis on public accountability and utility.
This should have resonance in globalisation and health
debates.
In the global context, there is a need for a vision of
what future policies and infrastructures for health
research should be. An interdisciplinary mix of skills is
required; teams that have flexibility and sufficient skills
to tackle both short and long-term questions; ability to
learn from and contribute to international experience;
capacities for the staff to retain their career trajectories
and respond to changing policy and research priorities.
At the same time, there should be programmes and
funding which encourages this research, with a stature
equivalent to the biological and technical sciences. Pub-
lic health combines medical and social sciences, and
public-health research is disseminated through interna-
tional publications, meetings, media and the internet.
The European Union, as well as national and interna-
tional programmes, must give more support to public
health research, and its standing in the global research
market, for it to be able to contribute fully to society.
Conclusions
For many centuries, global knowledge transfer has been
an important driver of cultural and economic develop-
ment. The European Commission is promoting science
for innovation both internally in European Union mem-
ber states and also through international transfer of peo-
ple and ideas. In the health field, the dominant bio-
medical model for research links innovation with phar-
maceutical research for profit. A second paradigm, of
McCarthy Globalization and Health 2011, 7:5
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Page 7 of 8social science for economic benefit, is particularly rele-
vant for global health. Further support is needed for
policies and partners, including civil society, to redress
the current emphasis on biotechnology research, aimed
at treatment, and to develop social sciences for preven-
tion and public health.
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